Figures & data
Table 1 Study characteristics.
Table 2 Results of the studies by country.
Oostenbrink JB, Rutten-van Molken M, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46 Schramm W, Haake D, Brandt A. Economic value of tiotropium (Spiriva®) in the treatment of chronic obstructive pulmonary disease. Praxis 2005;94:1803-1810 Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22:1599-1607 Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-135 Oostenbrink JB, Maiwenn J, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008;11:1070-1080 Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-749 Oostenbrink JB, Rutten-van Molken MP, van Noord JA, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241-249 Ramos P de Lucas, Miravitlles M, Gonzalez-Moro JM, et al. Cost-effectiveness analysis of the use of tiotropium compared with ipratropium in the treatment of patients with chronic obstructive pulmonary disease. PharmacoEconomics Spanish Research Articles 2004;1:121-128 Sanz-Martinez H, Perez-Maroto MT. Cost-efficacy analysis of tiotropium versus ipratropium and salmeterol in the treatment of chronic obstructive pulmonary disease. Farmacia Aten Primaria 2004;2:72-82 Garcia Ruiz AJ, Leiva Fernandez F, Martos Crespo F. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch Bronconeumol 2005;41:242-248 Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007;82:575-582 Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63:962-967 Reynoso FN. Effect of inhaled salbutamol-ipratropium and salbutamol-tiotropium combinations and oral theophylline in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Rev Inst Nal Enf Resp Mex 2006;19:122-126 Sicras-Mainar A, Velasco-Velasco S, Llopart-Lopez JR, et al. Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population. Aten Primaria 2007;39:547-555 Drescher GS, Carnathan BJ, Imus S, et al. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs. Respir Care 2008;53:1678-1684 Onukwugha E, Mullins CD, DeLisle S. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs Health Care System. Value Health 2008;11:980-988 Dalal A, Petersen H, Simoni-Wastila L, et al. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 µg/salmeterol 50 µg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ 2009;12:339-347